[go: up one dir, main page]

EE200200242A - Meetod suhkurtõve raviks - Google Patents

Meetod suhkurtõve raviks

Info

Publication number
EE200200242A
EE200200242A EEP200200242A EEP200200242A EE200200242A EE 200200242 A EE200200242 A EE 200200242A EE P200200242 A EEP200200242 A EE P200200242A EE P200200242 A EEP200200242 A EE P200200242A EE 200200242 A EE200200242 A EE 200200242A
Authority
EE
Estonia
Prior art keywords
treating diabetes
diabetes
treating
Prior art date
Application number
EEP200200242A
Other languages
English (en)
Inventor
Anne Piper Beth
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200200242A publication Critical patent/EE200200242A/et
Publication of EE05260B1 publication Critical patent/EE05260B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200242A 1999-11-03 2000-10-13 Metformiini ja glburiidi kombinatsiooni v„ikese annuse kasutamine 2. tpi suhkrut?ve esimese rea raviks EE05260B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes
PCT/US2000/028311 WO2001032157A2 (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and glibenclamide

Publications (2)

Publication Number Publication Date
EE200200242A true EE200200242A (et) 2003-12-15
EE05260B1 EE05260B1 (et) 2010-02-15

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200242A EE05260B1 (et) 1999-11-03 2000-10-13 Metformiini ja glburiidi kombinatsiooni v„ikese annuse kasutamine 2. tpi suhkrut?ve esimese rea raviks

Country Status (23)

Country Link
EP (1) EP1229918B1 (et)
JP (1) JP5183844B2 (et)
KR (1) KR20070089259A (et)
CN (1) CN1450902A (et)
AR (1) AR026356A1 (et)
AT (1) ATE390140T1 (et)
AU (1) AU780106B2 (et)
BR (1) BR0015294A (et)
CA (1) CA2389928C (et)
EE (1) EE05260B1 (et)
HU (1) HU229352B1 (et)
IL (1) IL149139A0 (et)
LT (1) LT5058B (et)
LV (1) LV12910B (et)
MX (1) MXPA02004282A (et)
NO (1) NO330026B1 (et)
NZ (1) NZ518278A (et)
PL (1) PL199278B1 (et)
RU (1) RU2275915C2 (et)
SK (1) SK287810B6 (et)
TW (1) TWI280125B (et)
UY (1) UY26424A1 (et)
WO (1) WO2001032157A2 (et)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US20080090859A1 (en) * 2003-10-30 2008-04-17 Tioga Pharmaceuticals, Inc. Use of Selective Opiate Receptor Modulators In the Treatment Of Neuropathy
KR101329369B1 (ko) * 2003-12-19 2013-11-14 오메가 바이오 파마(아이.피.3) 리미티드 당뇨 치료용 조성물 및 방법
CA2565250C (en) * 2004-05-03 2013-11-12 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
UA98799C2 (ru) 2007-07-19 2012-06-25 Такеда Фармасьютикал Компани Лимитед Твердый препарат, включающий алоглиптин и гидрохлорид метформина
SI2200606T1 (sl) 2007-09-10 2017-12-29 Janssen Pharmaceutica N.V. Postopek za pripravo spojin, uporabnih kot inhibitorjev SGLT
RU2372911C1 (ru) * 2008-03-12 2009-11-20 Николай Евгеньевич Староверов Полиморфная аналоговая терапия
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CN103736082A (zh) 2008-10-17 2014-04-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
ES2596291T3 (es) 2010-05-11 2017-01-05 Janssen Pharmaceutica, N.V. Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
TW201236692A (en) * 2011-02-02 2012-09-16 Sanofi Aventis Deutschland Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
KR102578030B1 (ko) 2014-12-12 2023-09-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 글라진／릭시세나티드 고정비 제형
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
CA2294582C (en) 1997-06-18 2008-02-12 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and metformin
CA2312990C (en) * 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
ATE250418T1 (de) * 1998-07-15 2003-10-15 Merck Sante Sas Tabletten enthaltend eine kombination von glibenclamid und metformin
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
AU780106B2 (en) 2005-03-03
NZ518278A (en) 2004-10-29
ATE390140T1 (de) 2008-04-15
HUP0300218A3 (en) 2006-02-28
EP1229918A2 (en) 2002-08-14
CN1450902A (zh) 2003-10-22
MXPA02004282A (es) 2003-02-17
JP5183844B2 (ja) 2013-04-17
CA2389928C (en) 2010-03-23
EE05260B1 (et) 2010-02-15
EP1229918B1 (en) 2008-03-26
LT2002063A (en) 2003-06-25
NO20022087L (no) 2002-06-24
AU1082601A (en) 2001-05-14
LV12910B (en) 2003-05-20
RU2275915C2 (ru) 2006-05-10
SK287810B6 (sk) 2011-10-04
JP2003519621A (ja) 2003-06-24
NO20022087D0 (no) 2002-05-02
WO2001032157A2 (en) 2001-05-10
HUP0300218A2 (hu) 2003-06-28
WO2001032157A3 (en) 2002-01-24
RU2002114820A (ru) 2004-03-10
AR026356A1 (es) 2003-02-05
NO330026B1 (no) 2011-02-07
SK5002002A3 (en) 2004-05-04
LT5058B (lt) 2003-09-25
IL149139A0 (en) 2002-11-10
PL199278B1 (pl) 2008-09-30
BR0015294A (pt) 2003-07-15
UY26424A1 (es) 2001-05-31
KR20070089259A (ko) 2007-08-30
PL364885A1 (en) 2004-12-27
HU229352B1 (en) 2013-11-28
TWI280125B (en) 2007-05-01
CA2389928A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
EE200200242A (et) Meetod suhkurtõve raviks
FI20000863L (fi) Uusi hoitomenetelmä
ID30339A (id) Metode pengobatan baru
ID30025A (id) Metode perlakuan tekstil
DE60028849D1 (de) Sterilisationsmethode
ID25682A (id) Metode untuk melelehkan kaca
NO331109B1 (no) Fremgangsmate for a utvide et rorformet element i en bronn
DE60030210D1 (de) Elektrolytisches Behandlungsverfahren
EA199900124A3 (ru) Способ лечениясердечной недостаточности
NO20010953L (no) En fremgangsmåte for behandling av stafylokokkal sykdom
FI19992807L (fi) Menetelmä ja järjestely häiriön poistamiseksi
NO20001089D0 (no) Mønstergjenkjenningsmetode
NO20013337L (no) Ny behandling
FI990509L (fi) Häiriönpoistomenetelmä
PT1228056E (pt) Metodo de preparacao de citaloprame
FI19992215A7 (fi) Kalanterointimenetelmä
DE50005753D1 (de) Montageverfahren
NO20006383L (no) Fremgangsmåte for behandling
EE200200350A (et) Ühend ja meetod valu raviks
DE69936533D1 (de) Neue behandlungsmethode
FI990861L (fi) Menetelmä ja järjestely puhelun muodostamiseksi
UA34041A (uk) Спосіб лікування цукрового діабету
ID26641A (id) Metoda pengobatan
SE9802791D0 (sv) Behandlingsmetod
UA33970A (uk) Спосіб лікування періодонтиту

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231